Last reviewed · How we verify

Adecatumumab and FOLFOX

Amgen Research (Munich) GmbH · Phase 2 active Small molecule

Adecatumumab and FOLFOX is a Monoclonal antibody, Chemotherapy Small molecule drug developed by Amgen Research (Munich) GmbH. It is currently in Phase 2 development for Colorectal cancer.

Adecatumumab is a monoclonal antibody targeting EpCAM, while FOLFOX is a chemotherapy regimen combining oxaliplatin, 5-fluorouracil, and leucovorin.

Adecatumumab is a monoclonal antibody targeting EpCAM, while FOLFOX is a chemotherapy regimen combining oxaliplatin, 5-fluorouracil, and leucovorin. Used for Colorectal cancer.

At a glance

Generic nameAdecatumumab and FOLFOX
SponsorAmgen Research (Munich) GmbH
Drug classMonoclonal antibody, Chemotherapy
TargetEpCAM
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 2

Mechanism of action

Adecatumumab works by binding to EpCAM, a protein expressed on the surface of certain cancer cells, potentially leading to their destruction. FOLFOX, on the other hand, is a combination chemotherapy regimen that targets rapidly dividing cancer cells.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Adecatumumab and FOLFOX

What is Adecatumumab and FOLFOX?

Adecatumumab and FOLFOX is a Monoclonal antibody, Chemotherapy drug developed by Amgen Research (Munich) GmbH, indicated for Colorectal cancer.

How does Adecatumumab and FOLFOX work?

Adecatumumab is a monoclonal antibody targeting EpCAM, while FOLFOX is a chemotherapy regimen combining oxaliplatin, 5-fluorouracil, and leucovorin.

What is Adecatumumab and FOLFOX used for?

Adecatumumab and FOLFOX is indicated for Colorectal cancer.

Who makes Adecatumumab and FOLFOX?

Adecatumumab and FOLFOX is developed by Amgen Research (Munich) GmbH (see full Amgen Research (Munich) GmbH pipeline at /company/amgen-research-munich-gmbh).

What drug class is Adecatumumab and FOLFOX in?

Adecatumumab and FOLFOX belongs to the Monoclonal antibody, Chemotherapy class. See all Monoclonal antibody, Chemotherapy drugs at /class/monoclonal-antibody-chemotherapy.

What development phase is Adecatumumab and FOLFOX in?

Adecatumumab and FOLFOX is in Phase 2.

What are the side effects of Adecatumumab and FOLFOX?

Common side effects of Adecatumumab and FOLFOX include Diarrhea, Fatigue, Nausea, Neutropenia, Vomiting.

What does Adecatumumab and FOLFOX target?

Adecatumumab and FOLFOX targets EpCAM and is a Monoclonal antibody, Chemotherapy.

Related